

Grammatical errors:

- Line 44-46 – grammatical error, “which shows”, would suggest paraphrasing that sentence
- Line 53-56 – please paraphrase it given grammatical error. Also, would suggest breaking the sentence into two.
- Line 68-72 – please paraphrase those lines, as there are prominent grammatical errors. Also, as a part of SEER database – you “evaluated” this patient population, not “enrolled”
- Line 77 – please revise the statement, given grammatical error
- Line 80 – Patients “P” should be rather “patients”
- Line 81 – “In addition” should be “in addition”
- Line 82-83, please fix the grammatical error, paraphrase the sentence
- Line 93-95 – please paraphrase the lines, given grammatical error
- Line 112-113 – please paraphrase, while defining which one is particularly “more”
- Line 124-125 – avoid the use of word “and” frequently, or try to combine the lines or either split the sentence into two
- Line 131-135 – please paraphrase these sentences, as given the way they are stated, there is lot of ambiguity
- Line 136 – please change “didn’t” to “did not”
- Line 147-148 – please paraphrase, given grammatical error
- Line 175-179 – please paraphrase it to state that graphs showed OS difference with RAI use in stages I-IV.
- Line 181 – paraphrase the section which states “patients suffered lymph node metastasis” – as it’s a consequence of cancer, you can restate that line as “patients who had lymph node metastases”
- Line 183-186 – please paraphrase and state the conclusions clearly
- Line 197-198 – please paraphrase the line, given grammatical error
- Line 238 – you can omit “solid” from the sentence
- 
- 
- Line 76 – you don’t have to re-define SEER, as it was already done on lines 68-69
- Line 35, 86 – expand the acronym AJCC TNM – as that’s being used for the first time
- Line 189 – you don’t have re-state the full form for acronym HCC, as this has been used numerous times before and you stated the full form initially already.
- Line 239 – what “extension” please state that clearly
- 
- 
- Would be nice to see individually as opposed to just I-II and III-IV. Breaking them and looking at that would be more beneficial.

- In discussion talk about whats being done currently from clinical trials standpoint, or what has already been done to address this issue